

Corrigendum

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”

Hugo Prazeres,^{1,2,3} Joana Torres,¹ Fernando Rodrigues,⁴ Joana P. Couto,^{1,3} João Vinagre,^{1,3,5} Manuel Sobrinho-Simões,^{1,3,6} and Paula Soares^{1,3}

¹Cancer Biology Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal

²Molecular Pathology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98, 3000-075 Coimbra, Portugal

³Department of Pathology, Faculty of Medicine of Porto University, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

⁴Endocrinology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98, 3000-075 Coimbra, Portugal

⁵Abel Salazar Biomedical Sciences Institute (ICBAS), Lg. Prof. Abel Salazar, 4099-003 Porto, Portugal

⁶Department of Pathology, Hospital São João, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Correspondence should be addressed to Paula Soares; psoares@ipatimup.pt





Received 14 March 2016; Accepted 25 May 2016

Copyright © 2016 Hugo Prazeres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer” [1], the following sentence should be added to the “Acknowledgments” section: This work was also supported by FEDER funds through Programa Operacional Factores de Competitividade (COMPETE) (FCOMP-01-0124-FEDER 011267).

References

- [1] H. Prazeres, J. Torres, F. Rodrigues et al., “How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer,” *Journal of Thyroid Research*, vol. 2011, Article ID 678357, 10 pages, 2011.



The Hindawi logo consists of two interlocking circles, one blue and one green, forming a stylized infinity or double helix symbol.

Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

